Target intelligence / Profile preview

Alsin Rho guanine nucleotide exchange factor ALS2 (ALS2)

Target
ALS2
Molecular classification
Guanine nucleotide exchange factor (GEF), Rho guanine nucleotide exchange factor, VPS9 domain-containing protein, RCC1-like domain-containing protein
01

Overview

Alsin Rho guanine nucleotide exchange factor ALS2 is a multidomain protein encoded by the ALS2 gene that serves as a guanine nucleotide exchange factor (GEF) for small GTPases, primarily Rab5 and Rac1. Alsin is highly expressed in the central nervous system, especially in motor neurons of the brain and spinal cord, where it regulates endosomal trafficking, cytoskeletal remodeling, and neuronal outgrowth. Disruption of ALS2 function through gene mutation causes inherited neurodegenerative syndromes including juvenile-onset amyotrophic lateral sclerosis (ALS2), infantile-onset ascending hereditary spastic paralysis, and juvenile primary lateral sclerosis. These disorders manifest as progressive muscle weakness and degeneration of upper motor neurons, thought to arise from defects in endocytic vesicle processing, receptor recycling, and cytoskeletal maintenance, for which alsin is essential. There are currently no known direct pharmacological therapies targeting ALS2, and its major relevance is in neurogenetic diagnostics and disease pathogenesis.

Other names
AlsinALS2CR6KIAA1563Amyotrophic lateral sclerosis 2 proteinIAHSPALSJPLSJAmyotrophic lateral sclerosis 2 (juvenile)ALS2_HUMAN
02

Biological functions

Activation of Rab5 and Rac1 small GTPasesRegulation of endocytosis and endosomal traffickingCytoskeletal remodeling and actin dynamicsNeurite outgrowth and axonal extensionMaintenance of neuronal homeostasis and receptor trafficking
03

Disease associations

Neurodegenerative disease (especially juvenile-onset motor neuron diseases)Amyotrophic lateral sclerosis type 2 (ALS2)Juvenile primary lateral sclerosisInfantile-onset ascending hereditary spastic paralysis
04

Safety considerations

Gene mutations lead to progressive motor neuron degeneration, but there are no direct therapeutic safety concerns since it is not a drug target at present.Challenges in gene therapy or molecular intervention could include off-target effects in neurons and potential impact on vesicular and cytoskeletal dynamics

Beyond the preview

Go deeper on Alsin Rho guanine nucleotide exchange factor ALS2 (ALS2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alsin Rho guanine nucleotide exchange factor ALS2 (ALS2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call